Stryker Corporation vs BIO-TECHNE Corp — how do they compare? Stryker Corporation trades at $319.04 (market cap $122.35B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Stryker Corporation is far larger — about 11× BIO-TECHNE Corp's market cap, and Stryker Corporation pays the higher dividend (1%). Which is the better fit depends on your goals.
| SYK | TECH | |
|---|---|---|
Market Cap | $122.35B | $11.16B |
Sector | Technology | Health |
52-Week High | $403.53 | $72.12 |
52-Week Low | $282.58 | $43.31 |
Enterprise Value | $134.10B | $11.24B |
Dividend Yield | 1% | 0.45% |
Trailing returns across standard periods
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →